|
| |
CODE:
LL-GI6646-L13
|
| |
Imaging and Workup of Pancreatic Islet Cell Tumors: An Evidence-based Review
|
| |
| |
| |
DATE: |
Wednesday, November 28 2007
|
| |
EXHIBIT HOURS: |
Sun. 8:00 AM - 6:00 PM
Mon. - Thurs. 7:00 AM - 10:00 PM
Fri. 7:00 AM - 12:45 PM
|
| |
LOCATION: |
|
| |
DISCLOSURES |
| |
V.S.
|
- Nothing to disclose.
|
|
| |
S.R.
|
- Nothing to disclose.
|
|
| |
S.B.
|
- Nothing to disclose.
|
|
| |
D.M.
|
- Nothing to disclose.
|
|
| |
H.R.
|
- Nothing to disclose.
|
|
| |
D.L.
|
- Consultant, Siemens AG
Consultant, EZM Incorporated
Consultant, Vital Images, Inc
Consultant, General Electric Company
Speaker, General Electric Company
Consultant, RITA Medical Systems, Inc
Speaker, RITA Medical Systems, Inc
Consultant, Boston Scientific Corporation
Speaker, Boston Scientific Corporation
Consultant, Endocare, Inc
Research funded, Endocare, Inc
Consultant, Tyco Healthcare (Valleylab)
Speaker, Tyco Healthcare (Valleylab)
Research funded, Tyco Healthcare (Valleylab)
|
|
| | PURPOSE/AIM |
| |
Pancreatic islet cell tumors are a heterogenous group of tumors that may be challenging to diagnose and localize. A properly sequenced pancreatic MDCT or MR is a critical first step for localization and characterization and may obviate a variety of additional tests such as endoscopic ultrasound, scintigraphy, PET, & angography.
|
| | |
| | CONTENT ORGANIZATION |
| |
In this exhibit, we will:
1. Provide a broad clinical overview of pancratic islet cell tumors including: insulinomas, glucagonomas, VIPomas, gastrinomas & carcinoids. 2. Provide MDCT & MR imaging protocols to enable diagnosis. 3. Review typical & atypical MDCT & MR imaging features of these lesions. 4. Provide an evidence based review of the efficacy of MDCT, MR, EUS, Scintigraphy, PET & Angiography in diagnosis. 5. Provide an algorithm for workup if multiple modalities are necessary.
|
| | |
| | SUMMARY |
| |
Summary: The major teaching points of this exhibit are:
1. Islet Cell tumors are a heterogenous group of lesions which may be challenging to diagnose clinically & by imaging
2. Contemporary MDCT and/or MR enable detection &
characterization of the majority (90%) of islet cell tumors.
3. Imaging technique is critical
4. EUS, Scintigraphy,PET and Angiography are complementary techniques for detection and localization.
|
| | |
|
QUESTIONS ABOUT THIS EVENT EMAIL: |
|
sraman@mednet.ucla.edu |
|
